Featured Research

from universities, journals, and other organizations

Genomic Signatures Identify Targeted Therapies For Lung Cancer

Date:
June 4, 2007
Source:
Duke University Medical Center
Summary:
Any number of things can go wrong in the cells of the body to cause cancer -- and clinicians can't tell by just looking at a tumor what exactly triggered the once normal cells to turn cancerous.

Any number of things can go wrong in the cells of the body to cause cancer -- and clinicians can't tell by just looking at a tumor what exactly triggered the once normal cells to turn cancerous.

Related Articles


New tests developed by researchers at Duke University can determine the precise patterns among thousands of genes to identify the cascade of events, or pathways, that led to the cancer.

These "genomic signatures" will give clinicians the tools they need to pursue alternatives to the traditional blunt force of chemotherapy. Following this test, patients might be treated with drugs that specifically target the faulty pathway, the researchers said.

"Traditional chemotherapy is not always effective," said Anil Potti, M.D., the study's lead investigator and an assistant professor of medicine in the Duke Institute for Genome Sciences & Policy. "Even when we are able to match the right chemotherapy with the right patient, 70 percent of patients with lung cancer may not respond to therapy. We need to take a different approach to those patients, and that is where these targeted therapeutics come in."

Potti and colleagues presented their findings on Sunday, June 3, at the annual meeting of the American Society for Clinical Oncology, in Chicago. The work was funded by the Jimmy V Foundation and the National Institutes of Health.

Mutations in individual cancer-causing genes, called oncogenes, set off a cascade of changes in the activity of hundreds of other interacting genes -- either increasing or decreasing their activity.

Rather than looking at each of these oncogenes individually, this new method presents a more global view by identifying the pathway encompassing all of the gene mutations that could have caused that cancer, Potti said.

The genomic test can theoretically apply to any cancer, but the Duke team focused on lung cancer because the survival rate is just 15 percent. Lung cancer now kills more Americans each year than breast, prostate and colorectal cancers combined.

The tests work by scanning thousands of genes in cells taken from the tumors of cancer patients and kept alive in laboratory cultures to produce a genomic profile of the tumor's molecular makeup. These patterns led to the identification of defective pathway in patients with both early stage and advanced disease. In particular, tumors with defects in two specific pathways -- called Src and Myc -- had much worse prognosis than those with defects in another pathway, called Ras.

The researchers then treated the laboratory tumors with drugs that specifically blocked one of the three different pathways. In all cases, the cancer responded to treatment with the appropriate targeted therapy.

Targeted therapeutics such as this could be "smart bombs" in comparison to the standard chemotherapy that obliterates all the cells that are actively reproducing.

Hundreds of drugs are currently available to target specific pathways. But because these therapies are effective only in a small percentage of patients, the majority of these drugs go unused.

Potti said the genomic signature tests would give patients another option to traditional chemotherapy. The Duke team plans to begin a clinical trial of the genomic tests in lung cancer patients this year.

"We hope that using this research to selectively add targeted drugs to current chemotherapy regimens will increase the response rate dramatically for patients with lung cancer," Potti said.

Other researchers participating in the study were Holly Dressman, Andrea Bild, Michael Kelley, Jeffrey Crawford, David Harpole, Geoffrey Ginsburg and Joseph Nevins.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Genomic Signatures Identify Targeted Therapies For Lung Cancer." ScienceDaily. ScienceDaily, 4 June 2007. <www.sciencedaily.com/releases/2007/06/070603215435.htm>.
Duke University Medical Center. (2007, June 4). Genomic Signatures Identify Targeted Therapies For Lung Cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2007/06/070603215435.htm
Duke University Medical Center. "Genomic Signatures Identify Targeted Therapies For Lung Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/06/070603215435.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins